Brouya schreef op 27 mei 2019 08:59:
GENFIT Launches a Combination Therapy Clinical Program in NASH
GENFIT has identified multiple therapeutic compounds synergistic with its lead asset, elafibranor (PPAR alpha/delta), for the treatment of NASH
Combined metabolic mechanisms could offer optimal benefits by addressing the underlying drivers of NASH disease progression and its downstream consequence, fibrosis, through complementary pathways
A proof of concept study will initiate in 2H19 to evaluate safety, tolerability and exploratory markers of efficacy of a GLP-1 receptor agonist or an SGLT2 inhibitor in combination with elafibranor as backbone therapy
This program will leverage non-invasive diagnostic tools, including GENFIT’s NIS4, an innovative diagnostic blood test for NASH identification and monitoring
www.globenewswire.com/news-release/20...